939P Efficacy and safety of a novel anti-EGFR ADC MRG003 in recurrent or metastatic squamous cell carcinoma of the head and neck patients

医学 内科学 肿瘤科 头颈部鳞状细胞癌 头颈部 基底细胞 头颈部癌 表皮生长因子受体 癌症研究 癌症 外科
作者
L. Xue,Y. Han,Q. Zhang,Xiaoling Li,M. Fang,L. Zhong,S. Wang,Ying Liu,S. Zhang,Yi Guo
出处
期刊:Annals of Oncology [Elsevier BV]
卷期号:34: S590-S590 被引量:13
标识
DOI:10.1016/j.annonc.2023.09.2083
摘要

Patients (pts) with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) who failed platinum and/or immune check-point inhibitor have a poor prognosis with OS~6 moths. Epidermal growth factor receptor (EGFR) is aberrantly over-expressed in R/M SCCHN pts with high frequency. MRG003 is a novel ADC composed of a humanized anti-EGFR mAb conjugated to MMAE via a vc-linker. This study was designed to evaluate the efficacy and safety of MRG003 in R/M SCCHN. Histologically or cytologically confirmed R/M SCCHN (including oral cavity, oropharynx, hypopharynx, and larynx) pts were divided into two groups of MRG003 (2.0 or 2.3 mg/kg, Q3W). Eligible pts were aged 18-75 years old and had progressed at least one line of standard therapy. The primary endpoint was the objective response rate (ORR). The secondary endpoints included disease control rate (DCR), median progression-free survival (mPFS), median overall survival (mOS), and safety. Sixty-seven pts in total were enrolled with 35 pts received 2.0 mg/kg of MRG003, and 32 pts received 2.3 mg/kg. The median age was 54 (26-75) years, and 91% of pts’ ECOG performance status was 1. The immunohistochemistry detection of EGFR expression was performed in 65 pts, and 62 pts (95.4%) were EGFR-positive. The median line of prior therapy was 2 (1-5). Most pts had received prior platinum (95.6%), PD-1/L1 inhibitor (76.1%), cetuximab (47.8%). At the data cutoff, the ORR was 30.6% in all EGFR-positive pts. In the 2.3 mg/kg dose group, the ORR and DCR was 43% and 86% in 2/3-line pts who had failed prior platinum and PD-1/L1 inhibitor, and the mPFS and mOS were 4.2 months and 11.3 months, respectively. The common treatment-related adverse events (TRAEs) included constipation (25.8%), pruritus (24.2%), and anemia (22.6%). Common grade 3 or above TRAEs included white blood cell count decreased (6.5%), anemia (4.8%). MRG003 was well tolerated with a manageable safety profile, and showed promising efficacy in 2/3-line R/M SCCHN pts who failed prior platinum and PD-1/L1inhibitor. A phase III study is currently ongoing to further explore the efficacy of MRG003 in compared with cetuximab/methotrexate in this setting.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Fun_112发布了新的文献求助10
刚刚
Owen的应助被十一采纳,获得10
刚刚
BingFeiLi发布了新的文献求助10
刚刚
有才的老妖怪完成签到 ,获得积分10
1秒前
1秒前
科研通AI65的应助被luoluo采纳,获得10
1秒前
MICO完成签到,获得积分10
1秒前
浮名半生完成签到,获得积分10
1秒前
星辰大海的应助被粗犷的天佑采纳,获得10
2秒前
orixero的应助被lll采纳,获得10
2秒前
2秒前
zzz发布了新的文献求助10
2秒前
外向夜阑发布了新的文献求助10
2秒前
科研通AI65的应助被keggin采纳,获得10
3秒前
zzz发布了新的文献求助10
3秒前
pengdaiyun发布了新的文献求助10
3秒前
4秒前
汉堡包的应助被pd采纳,获得10
4秒前
5秒前
5秒前
5秒前
无极微光的应助被坦率尔琴采纳,获得20
5秒前
万椿完成签到,获得积分10
6秒前
Scihubwangxy发布了新的文献求助10
6秒前
6秒前
mxc发布了新的文献求助10
6秒前
黄某完成签到,获得积分20
7秒前
SciGPT的应助被如懿采纳,获得10
7秒前
7秒前
Re发布了新的文献求助10
7秒前
8秒前
9秒前
wz发布了新的文献求助10
10秒前
EI完成签到,获得积分10
10秒前
许分婷发布了新的文献求助10
10秒前
11秒前
shuyiWang发布了新的文献求助10
11秒前
一一完成签到,获得积分10
11秒前
小石发布了新的文献求助10
11秒前
Ausna发布了新的文献求助10
11秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8178102
求助须知:如何正确求助?哪些是违规求助? 9568769
关于积分的说明 21801545
捐赠科研通 7772898
什么是DOI,文献DOI怎么找? 3432613
关于科研通互助平台的介绍 2556748
邀请新用户注册赠送积分活动 2478199